Please assess the completion status of the following clinical trial:

Trial Title: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe plaque psoriasis~* Loss of satisfactory response to adalimumab~* Currently receiving or recently discontinued treatment with adalimumab~Exclusion Criteria:~* Active skin conditions that would interfere with evaluations of the effect of investigational product on psoriasis~* Serious medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etanercept 50 mg (Type: EXPERIMENTAL): Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).